[{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Inapplicable"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Sosei Heptares \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Valeo Pharma"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Propeller Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Propeller Health","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Propeller Health"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Propeller Health","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Propeller Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Propeller Health \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Propeller Health \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Indacaterol Acetate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Vectura Ltd \/ Novartis Pharmaceuticals Corporation"}]

Find Clinical Drug Pipeline Developments & Deals for Indacaterol Acetate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Details : QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 07, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Novartis Pharmaceuticals Corporation

Deal Size : Inapplicable

Deal Type : Inapplicable

Skyepharma Company Banner

02

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair® Breezhaler® and Atectura® Breezhaler® for an initial 8 year period.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

March 29, 2021

Lead Product(s) : Indacaterol Acetate,Mometasone Furoate

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Valeo Pharma

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : New post hoc analysis results from the phase III IRIDIUM study that suggests that using Enerzair Breezhaler as a step-up therapy from medium-dose LABA/ICS provides benefit beyond increasing ICS dose alone.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

March 09, 2021

Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

04

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Patients using Enerzair® and Atectura® Breezhaler® to manage their uncontrolled asthma in Japan will have the option to enroll in Propeller’s digital health platform to help manage their condition.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Undisclosed

August 26, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Novartis Pharmaceuticals Corporation

Deal Size : Undisclosed

Deal Type : Collaboration

blank

05

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 09, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

06

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : European Commission approves once-daily Enerzair® Breezhaler® in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 07, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrrolate

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

07

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : For the first time in Japan, a new digital device combining a sensor with the Breezhaler® inhaler is being made available. Announcement by Novartis Pharma K. K. highlights key milestone for once-daily Enerzair® (IND/GLY/MF) complete with new sensor-ena...

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 29, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Approved FDF

Sponsor : Novartis Pharmaceuticals Corporation

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

08

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily Tio in improving quality of life in people with uncontrolled asthma.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 06, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrrolate

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase III

Sponsor : Novartis Pharmaceuticals Corporation

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

09

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : If the EC follows this recommendation and approves Enerzair® Breezhaler®, it will become the first LABA/long-acting muscarinic antagonist (LAMA)/ICS fixed-dose combination for uncontrolled asthma patients.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 05, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrrolate

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

10

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Decision supported by robust efficacy and safety data from Phase III IRIDIUM study, in which once-daily Enerzair® Breezhaler® resulted in statistically significant improvements in lung function.

Product Name : Enerzair Breezhaler

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 05, 2020

Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase III

Sponsor : Propeller Health

Deal Size : Inapplicable

Deal Type : Inapplicable

blank